- Di processo
- The presentation on this topic provides a foundation for understanding the
mechanisms driving metabolic diseases, setting the stage for subsequent discussions on
masld/mash pathophysiology. Given the increasing prevalence of metabolic-associated liver
disease, emerging insights into its underlying mechanisms and new diagnostic and treatment
strategies are crucial. The second day begins with discussions on the distinction between clinical
and preclinical obesity, an evolving concept that has significant implications for both treatment
and prevention. Clarifying these definitions is essential for refining diagnostic criteria, identifying
individuals at risk, and implementing targeted interventions. The prevalence of these obesity
subtypes will be explored, followed by a round table discussion where experts will debate the most
- Professionali
- Obesity and its related metabolic disorders remain some of the most pressing public health
challenges of our time, requiring a multidisciplinary approach to understand their pathophysiology,
clinical implications, and treatment strategies. This meeting brings together experts from various
fields to provide a comprehensive overview of obesity, metabolic dysfunction-associated steatotic
liver disease (masld), and their interconnections with metabolic and cardiovascular health. The
meeting begins with an introduction, setting the stage for discussions that blend scientific insights
with broader reflections on competition and perseverance, as illustrated by the historical rivalry
between bernini and borromini. This thematic introduction serves as a metaphor for scientific
progress, emphasizing the importance of collaboration and innovation in advancing medical
research. A key focus of the meeting is the dysfunction of adipose tissue and its impact on obesity
and liver health.
- Di sistema
- For diagnosing and managing clinical obesity. Pharmacological treatment
remains a cornerstone of obesity management, and recent advancements in weight loss
medications warrant a dedicated session to provide a comprehensive overview of their efficacy,
safety, and place in therapy. Additionally, obesity in type 1 diabetes—a less frequently discussed
but clinically significant condition— will be examined to shed light on its prevalence and treatment
implications. Bariatric surgery continues to play a pivotal role in obesity management, even as
pharmacological approaches advance. The evolving relationship between surgery and medicationbased
treatments will be explored, with a focus on optimizing patient outcomes. Furthermore,
masld/mash will be examined from both hepatic and cardiometabolic perspectives, emphasizing
the need for tailored treatment strategies based on disease subtypes. The meeting will also
highlight novel insights